TOURMALINE BIO ($TRML) posted quarterly earnings results on Thursday, March 13th. The company reported earnings of -$0.86 per share, beating estimates of -$0.89 by $0 ...

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically ...

Shares of NASDAQ TRML opened at $18.80 on Friday. Tourmaline Bio has a 1-year low of $11.87 and a 1-year high of $45.55. The business has a 50-day moving average of $15.71 and a 200-day moving ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Tourmaline Bio (TRML – Research Report). The company’s shares closed yesterday at $12.94.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tourmaline Bio (TRML – Research Report) and Andlauer Healthcare Group (ANDHF – Research Report ...

The event will include presentations from Tourmaline's leadership team and Dr. Marc Bonaca, a cardiologist and vascular med Tourmaline Bio, Inc. ( (TRML) ) has released its Q3 earnings.